ArticleBMC cancer2025
Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phthalazine as a medically versatile polyheterocyclic core with underexplored anticancer potential.Journal of enzyme inhibition and medicinal chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is one of the most common malignancies and causes of mortality in women. Combination therapies are one of the treatment approaches that contribute to better performance, reduced dosage, and drug resistance. Hydralazine is an antihypertensive drug, but it can induce epigenetic changes such as DNA methylation reversal in cancer cells. ATRA is a type of vitamin A, and its deficiency is associated with the progression of various diseases. It can bind to receptors and regulate genes to inhibit multiple types of cancers.
methodsAccording to bioinformatics studies, combining these two drugs can inhibit breast cancer cells. This study investigates various biological pathways, such as HIF-1, VEGF, and WNT, with the key genes of CCND1, VEGFA, VEGFA2, HIF1A, and HIF1A-AS. In the laboratory, MDA-MB-231, as a tumor cell line, and MCF10, as a normal cell line, were cultured, and the MTT assay was performed to obtain the IC
resultsResults showed that hydralazine alone stimulated cancer cell growth, potentially inducing breast cancer. ATRA reduced cell survival in both normal and cancer cells. However, the combination treatment exhibited differential effects, causing a significant reduction in survival in cancer cells while the impact on normal cells was not significant.
conclusionsHydralazine/ATRA combination inhibits cancer cell proliferation and their adaptation to hypoxia. These findings suggest a potential for new treatment targeting breast cancer cells with minimized side effects. CLINICAL
trial registrationClinical trial number: "not applicable".
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.